The biggest question going into the J.P. Morgan Healthcare Conference every year is which big company is going to announce a large acquisition. Amgen, Inc. CEO Robert Bradway’s answer on 11 January at this year’s meeting is that there are not many opportunities out there for larger transactions at a feasible price, but there is a lot of smaller firms with technology that can help the company boost its longer-term research and development goals, like Arrakis Therapeutics.
Amgen and Arrakis announced prior to Bradway’s J.P. Morgan presentation that the companies entered into a research collaboration for the discovery and development of small molecules that degrade RNAs that encode disease-causing proteins as a novel approach to reaching difficult-to-drug targets in multiple therapeutic areas
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?